Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3823-3835

  Zou, Seyin ^a,c   Cao, Nuo ^a   Cheng, Du ^b   Zheng, Rongqin ^d   Wang, Jin ^d   Zhu, Kangshun ^d   Shuai, Xintao ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b School of Chemistry and Chemical Engineering   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Chemotherapy; Codelivery; Gene silencing; Tumor targeting

Indexed keywords

DOXORUBICIN; FOLATE RECEPTOR; FOLIC ACID; MACROGOL; NANOCARRIER; POLYCAPROLACTONE; POLYETHYLENEIMINE; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BCL 2 GENE; CANCER CELL DESTRUCTION; CELL MEDIATED CYTOTOXICITY; COVALENT BOND; CYTOTOXICITY TEST; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LINKAGE ANALYSIS; MICELLE; MOLECULAR INTERACTION; MOLECULAR WEIGHT; OVARY CANCER; PARTICLE SIZE; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; TUMOR GENE; UPREGULATION; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DOXORUBICIN; DRUG CARRIERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; FOLIC ACID; GENE SILENCING; GENES, BCL-2; HUMANS; OVARIAN NEOPLASMS; PARTICLE SIZE; POLYESTERS; POLYETHYLENEIMINE; RNA, SMALL INTERFERING;

EID: 84870310262     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29328     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Chauhan SC, Kumar D, Jaggi M. Mucins in ovarian cancer diagnosis and therapy. J Ovarian Res. 2009;2:21.
3. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002;7(Suppl 5):20-28.
4. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900-905.
5. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985;55(12):2761-2765.
6. Yallapu MM, Jaggi M, Chauhan SC. Scope of nanotechnology in ovarian cancer therapeutics. J Ovarian Res. 2010;3:19.
7. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185-229.
8. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62(6):865-872.
9. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1gene: recent views. Biochem Pharmacol. 2002;64(5-6):943-948.
10. Scatena CD, Stewart ZA, Mays D, etal. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem. 1998;273(46):30777-30784.
11. Dantzig AH, Shepard RL, Cao J, etal. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996;56(18):4171-4179.
12. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2(4):277-288.
13. Gross A. Mitochondrial carrier homolog 2: a clue to cracking the BCL-2 family riddle? J Bioenerg Biomembr. 2005;37(3):113-119.
14. Decaudin D, Geley S, Hirsch T, etal. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res. 1997;57(1):62-67.
15. Lima RT, Martins LM, Guimarães JE, Sambade C, Vasconcelos MH. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 2004;11(5):309-316.
16. Cao N, Cheng D, Zou S, Ai H, Gao J, Shuai X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials. 2011;32(8):2222-2232.
17. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26(1):57-64.
18. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater. 2006;5(10):791-796.
19. Zhu C, Jung S, Luo S, etal. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials. 2010;31(8):2408-2416.
20. Qiu LY, Bae YH. Self-assembled polyethylenimine-graft-poly(ε-caprolactone) micelles as potential dual carriers of genes and anticancer drugs. Biomaterials. 2007;28(28):4132-4142.
21. Cheng D, Cao N, Chen J, Yu X, Shuai X, Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. Biomaterials. 2012;33(4):1170-1179.
22. Shuai XT, Merdan T, Unger F, Wittmar M, Kissel T. Novel biodegradable ternary copolymers hy-PEI-g-PCL-b-PEG: synthesis, characterization, and potential as efficient nonviral gene delivery vectors. Macromolecules. 2003;36(15):5751-5759.
23. Cammas S, Nagasaki Y, Kataoka K. Heterobifunctional poly(ethylene oxide): synthesis of α-methoxy-ω-amino and α-hydroxy-ω-amino PEOs with the same molecular weights. Bioconjug Chem. 1995;6(2):226-230.
24. Mukhopadhyay P, Bátkai S, Rajesh M, etal. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007;50(6):528-536.
25. Chen GH, Chen WJ, Wu Z, etal. MRI-visible polymeric vector bearing CD3single chain antibody for gene delivery to T cells for immunosuppression. Biomaterials. 2009;30(10):1962-1970.
26. Wang DA, Narang AS, Kotb M, etal. Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules. 2002;3(6):1197-1207.
27. Panaretakis T, Pokrovskaja K, Shoshan MC, Grandér D. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem. 2002;277(46):44317-44326.
28. Giuliano M, Lauricella M, Vassallo E, Carabillo M, Vento R, Tesoriere G. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Invest Ophthalmol Vis Sci. 1998;39(8):1300-1311.
29. Poulaki V, Mitsiades CS, Joussen AM, Lappas A, Kirchhof B, Mitsiades N. Constitutive nuclear factor-kB activity is crucial for human retinoblastoma cell viability. Am J Pathol. 2002;161(6):2229-2240.
30. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H2O2-and p53-dependent pathways. J Biol Chem. 2004;279(24):25535-25543.
31. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997;22(8):299-306.
32. Petersen H, Fechner PM, Martin AL, etal. Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconjug Chem. 2002;13(4):845-854.
33. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41(2):147-162.
34. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res. 2008;41(1):120-129.
35. Clementi ME, Giardina B, Di Stasio E, Mordente A, Misiti F. Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res. 2003;23(3B):2445-2450.
36. Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem. 2001;276(50):47266-47276.
37. Gamen S, Anel A, Perez-Galan P, etal. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res. 2000;258(1):223-235.
38. Chen Y, Wan Y, Wang Y, Zhang H, Jiao Z. Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomedicine. 2011;6:2321-2326.
39. Panaretakis T, Laane E, Pokrovskaja K, etal. Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell. 2005;16(8):3821-3831.
40. Decaudin D, Geley S, Hirsch T, etal. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res. 1997;57(1):62-67.
41. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998;95(9):4997-5002.
42. Li P, Nijhawan D, Budihardjo I, etal. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91(4):479-489.
43. Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB. Bcl-2inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ. 2000;7(1):102-111.
44. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74(4):609-619.
45. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 1998;17(14):3878-3885.